The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

Şen, Sedat; Tuncer, Aslı; Özakbaş, Serkan; Uzunköprü, Cihat; Baba, Cavid; Demi̇r, Serkan; Beckmann, Yeşim; Gümüş, Haluk; Arslan, Gokhan; Altıntaş, Ayşe; Yüceyar, Nur; Turan, Ömer Faruk; Tütüncü, Melih; Terzı, Murat; Acar, Pinar; Bunul, Destan; Balcı, Belgin Petek; Bir, Levent Sinan; Köseoğlu, Mesrure; Mungan, Semra; Gündüz, Tuncay; Doğan, İbrahim; Kotan, Dilcan; Uygunoğlu, Uğur; Ekmekçi, Özgül; Demirkıran, Meltem; Kamışlı, Özden; Kabay, Sibel Canbaz; Tamam, Yusuf; Ömerhoca, Sami; Sevim, Serhan; Güler, Sibel; Kürtüncü, Murat; Efendı, Hüsnü; Karabudak, Rana; Síva, Aksel

doi:10.1016/j.msard.2021.103399

Cited by 6 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One Turkish multicenter study with 63 COVID-19 cases included patients with MOGAD in the analysis analogous to our study. 34 They described more similar outcomes (hospitalization: 22%; intensive care admission: 2%), which might indicate a milder course of COVID-19 in MOGAD but should be verified in larger studies. Owing to demographic and clinical differences, direct comparison again is not possible.…”

Section: Discussionmentioning

confidence: 85%

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Hümmert

Bütow²,

Tkachenko³

et al. 2023

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Background and ObjectivesTo evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated diseases (MOGAD).MethodsThis multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database.ResultsOne hundred eighty-seven patients (75% women; median age 47 [range 21–86] years; median disease duration 5.5 [range 0–67] years; median Expanded Disability Status Scale 2.0 [range 0–8.0]; 51% aquaporin-4 immunoglobulin G (AQP4-IgG)-positive, 36% myelin oligodendrocyte glycoprotein (MOG)-IgG-positive 13% double-seronegative) were analyzed. Most patients maintained excellent access to healthcare services throughout the pandemic. Immunotherapy was not changed in 88% of patients. Ninety-one percent of all patients were satisfied with medical care during the pandemic. Nearly two-thirds (64%) of patients rated their risk of infection with SARS-CoV-2 as low or moderate. Among this study sample, 23 patients (12%) knowingly acquired an infection with SARS-CoV-2 and predominantly had a nonsevere course of illness (n = 22/23, 96%). The SARS-CoV-2 vaccination rate was 89%, with 4 cases of confirmed attack or first manifestation of NMOSD/MOGAD occurring in temporal association with the vaccination (range 2–9 days). The reported HRQoL did not decline compared with a prepandemic assessment (mean EQ-5D-5L index value 0.76, 95% bootstrap confidence interval [CI] 0.72–0.80; mean EQ-VAS 66.5, 95% bootstrap CI 63.5–69.3).DiscussionThis study demonstrates that, overall, patients with NMOSD/MOGAD affiliated with specialized centers received ongoing medical care during the pandemic. Patients' satisfaction with medical care and HRQoL did not decrease.

show abstract

Section: Discussionmentioning

confidence: 85%

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Hümmert

Bütow²,

Tkachenko³

et al. 2023

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

show abstract

“…90 A Turkish registry found that only 2 out of 13 MOGAD patients had moderate/severe/ critical COVID-19, while most had mild disease, and there were no deaths reported. 91 There have been very few published cases of patients with existing MOGAD having relapses following COVID-19, though in one reported case, a relapse following mild COVID-19 symptoms correlated with serologic reappearance of anti-MOG antibody. 92…”

Section: Mogadmentioning

confidence: 94%

“…There was no difference in the hospitalization rate based on DMT use in this group. 91 In a Latin American registry of 16 NMOSD patients, 9 (56%) required hospitalization, and 5 (32%) died from COVID-19. 94 Though there are limited data on the risk of NMOSD relapse after COVID-19 infection, small studies suggest an increased risk.…”

Section: Nmosdmentioning

confidence: 99%

“…90 A Turkish registry found that only 2 out of 13 MOGAD patients had moderate/severe/critical COVID-19, while most had mild disease, and there were no deaths reported. 91…”

Section: Covid-19 Infection In Patients With Established Neuroimmunol...mentioning

confidence: 99%

Section: Covid-19 Infection In Patients With Established Neuroimmunol...mentioning

confidence: 99%

See 2 more Smart Citations

Central Nervous System Neuroimmunologic Complications of COVID-19

Holroyd

Conway

2023

Semin Neurol

View full text Add to dashboard Cite

Autoimmune disorders of the central nervous system following COVID-19 infection include multiple sclerosis (MS), neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, autoimmune encephalitis, acute disseminated encephalomyelitis, and other less common neuroimmunologic disorders. In general, these disorders are rare and likely represent postinfectious phenomena rather than direct consequences of the SARS-CoV-2 virus itself. The impact of COVID-19 infection on patients with preexisting neuroinflammatory disorders depends on both the disorder and disease-modifying therapy use. Patients with MS do not have an increased risk for severe COVID-19, though patients on anti-CD20 therapies may have worse clinical outcomes and attenuated humoral response to vaccination. Data are limited for other neuroinflammatory disorders, but known risk factors such as older age and medical comorbidities likely play a role. Prophylaxis and treatment for COVID-19 should be considered in patients with preexisting neuroinflammatory disorders at high risk for developing severe COVID-19.

show abstract

The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders

Zhong,

Wu,

Zhou

et al. 2024

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?

Cited by 6 publications

References 29 publications

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Central Nervous System Neuroimmunologic Complications of COVID-19

The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders

Contact Info

Product

Resources

About